Hexarelin

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) and one of the most potent compounds in the GHRP family for acute growth hormone release. Structurally related to GHRP-6 and GHRP-2, the hexarelin peptide activates the growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs, triggering a rapid, powerful pulse of GH secretion that exceeds the response produced by any other GHRP-class compound.[1][2]

What distinguishes hexarelin from other growth hormone releasing peptides is a dual pharmacological identity. Beyond its role as the strongest acute GH secretagogue in the GHRP family, hexarelin has demonstrated significant cardioprotective effects that operate independently of GH release — acting through CD36 scavenger receptors in cardiac tissue rather than the classical GHS-R1a pathway.[3][5] This makes hexarelin cardioprotection a unique research area that no other GHRP shares to the same degree.

The trade-off for hexarelin’s superior GH potency is pronounced desensitisation with repeated use. Unlike ipamorelin, which maintains its GH response during chronic exposure, hexarelin shows significant attenuation of GH release within weeks of continuous administration — a partial and reversible effect, but one that fundamentally shapes its research profile.[7]

Compound Profile

How Hexarelin Works

Hexarelin activates the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor targeted by endogenous ghrelin and other GHRPs. Imbimbo et al. (1994) established hexarelin’s dose-response profile in humans, demonstrating dose-dependent GH release with peak plasma GH concentrations reaching approximately 55 ng/mL at maximal doses — substantially higher than typical responses seen with GHRP-6 or GHRP-2.[1] Ghigo et al. (1997) provided a comprehensive review of the GHRP class, confirming that hexarelin and related growth hormone releasing peptides act through a distinct receptor pathway from GHRH analogs like sermorelin and CJC-1295.[2]

The critical mechanistic distinction for hexarelin growth hormone release is its dual-site action. At the pituitary level, GHS-R1a activation triggers intracellular calcium signalling and GH granule exocytosis. At the hypothalamic level, hexarelin stimulates endogenous GHRH release while partially overriding somatostatin’s inhibitory tone — a property that GHRH-pathway compounds do not share. This dual amplification produces the most potent acute GH pulse of any synthetic GHRP.[2]

Beyond GHS-R1a, hexarelin interacts with CD36 scavenger receptors — a non-GHS-R pathway that mediates its cardiovascular effects independently of GH secretion. Torsello et al. (2003) demonstrated that hexarelin’s cardioprotective activity in ischaemia-reperfusion models was largely mediated by CD36 interactions rather than GHS-R signalling.[5] This dual-receptor pharmacology is unique among GHRPs and represents hexarelin’s most distinctive mechanistic feature.

Recovery & Sleep Context

The recovery and sleep relevance of hexarelin centres on its potent stimulation of the GH axis. The largest natural GH pulse occurs during slow-wave sleep, driving tissue repair, protein synthesis, and glycogen replenishment. Hexarelin produces the strongest acute GH response in the GHRP class, making it a powerful research tool for studying GH-mediated recovery processes.[1][2]

The practical limitation for recovery and sleep applications is desensitisation. Rahim et al. (1998) demonstrated that chronic hexarelin therapy produced a significant and progressive decline in GH response over 16 weeks, reducing the AUC of GH release by approximately 45% compared to baseline.[7] This contrasts with ipamorelin, which maintains its GH response during sustained use. For recovery-focused research, hexarelin’s acute potency is unmatched, but sustained GH elevation requires consideration of tolerance patterns. Combining hexarelin with GHRH analogs like sermorelin or CJC-1295 may partially offset this limitation through complementary receptor-pathway stimulation.

Muscle Growth Context

The muscle growth interest in hexarelin operates through the GH → IGF-1 → anabolic signalling cascade. Sigalos and Pastuszak (2018) reviewed the GHS class comprehensively, documenting that growth hormone secretagogues increase lean body mass, decrease fat mass, and improve body composition through sustained GH-mediated anabolic effects.[8] Hexarelin’s superior acute GH potency theoretically positions it as the strongest driver of GH-mediated anabolism among GHRPs.

However, the desensitisation issue directly limits muscle growth applications. GH-mediated muscle accretion is a slow, cumulative process requiring sustained GH elevation over months. Hexarelin’s declining GH response during chronic exposure — documented clearly by Rahim et al. — means the initial potency advantage diminishes over the timescales most relevant to muscle growth.[7] This is why ipamorelin and GHRP-2, despite producing smaller acute GH pulses, may offer more consistent long-term support for muscle growth goals.

Hexarelin Cardioprotection

The most significant differentiator in hexarelin’s research profile is its cardioprotective activity — a property that operates through mechanisms independent of growth hormone release. Mao et al. (2014) provided a comprehensive review of hexarelin’s cardiovascular actions, establishing that CD36 scavenger receptors in cardiac tissue function as a specific cardiac receptor for hexarelin, mediating cardioprotective effects that are distinct from GHS-R1a-mediated GH secretion.[3]

Torsello et al. (2003) demonstrated this mechanism directly: in hypophysectomised rats (eliminating GH as a variable), hexarelin provided 60% protection against ischaemia-reperfusion damage to left ventricular end-diastolic pressure, compared to only 15% protection from ghrelin — confirming that hexarelin’s cardiac effects are largely CD36-mediated rather than GHS-R-dependent.[5]

Xu et al. (2012) extended these findings, showing that chronic hexarelin administration significantly attenuated cardiac fibrosis, left ventricular hypertrophy, and diastolic dysfunction in spontaneously hypertensive rats. The antifibrotic mechanism involved decreased collagen synthesis and accelerated collagen degradation via regulation of matrix metalloproteinases.[6] This hexarelin cardioprotection research represents a genuinely novel application that distinguishes the compound from every other GHRP in the class.

Performance Support Context

Hexarelin’s relevance to performance support is driven by its GH-axis activation and emerging cardiovascular research. GH elevation supports exercise recovery, substrate utilisation, and the maintenance of lean tissue — all relevant to performance support contexts. Hexarelin’s superior acute GH potency makes it the most powerful single-dose GHS for triggering the GH cascade that underpins performance-relevant physiological processes.[1][8]

The cardiovascular research adds a secondary performance dimension. Improved cardiac function, reduced ventricular remodelling, and antifibrotic effects — if translatable from preclinical models — could have implications for cardiovascular performance capacity.[6] However, hexarelin is a WADA prohibited substance, classified under the growth hormone secretagogue category, which limits its applicability in competitive athletic contexts.

Hexarelin Benefits

The hexarelin benefits profile is best understood through its established pharmacology and emerging research applications:

• Most potent acute GH release: Hexarelin produces the strongest single-dose GH response of any GHRP — exceeding GHRP-6, GHRP-2, and ipamorelin in peak GH concentrations.[1][2]
• Unique cardioprotective profile: CD36-mediated cardiac protection — reduced infarct size, attenuated fibrosis, and improved ventricular function — is a property no other GHRP shares to the same degree.[3][5][6]
• Dual-receptor pharmacology: Acts through both GHS-R1a (GH release) and CD36 (cardiovascular effects), providing two distinct research pathways in a single compound.
• Synergistic with GHRH analogs: Works through a complementary receptor pathway to sermorelin, CJC-1295, and tesamorelin, enabling dual-pathway GH amplification.
• Improved metabolic markers: Preclinical data suggests beneficial effects on lipid metabolism and body composition via CD36 receptor interactions.[5]
• Well-characterised pharmacokinetics: Decades of published research establishing dose-response, half-life (~70 minutes), and safety signals across multiple study designs.[1][2][8]

Hexarelin Side Effects

The hexarelin side effects profile reflects its potent but non-selective GHS-R1a activation:

• Cortisol and ACTH elevation: Korbonits et al. (1999) confirmed that hexarelin significantly stimulates the hypothalamo-pituitary-adrenal axis, producing measurable increases in both ACTH and cortisol. This effect is mediated via arginine vasopressin and is more pronounced than with ipamorelin.[4]
• Prolactin elevation: Dose-dependent prolactin increases accompany hexarelin’s GH release — a class effect shared with GHRP-6 but largely absent with ipamorelin.[4]
• Pronounced desensitisation: The most clinically significant hexarelin side effect is progressive attenuation of GH response. Rahim et al. (1998) documented approximately 45% reduction in GH release by week 16 of chronic therapy — reversible within 4 weeks of cessation.[7]
• Appetite stimulation: Moderate ghrelin-pathway activation produces appetite increase, though less pronounced than the intense hunger associated with GHRP-6.[4]
• Water retention: GH-mediated fluid retention, dose-dependent and reversible. Standard across the GHS class.
• WADA prohibited: Classified as a prohibited substance under World Anti-Doping Agency guidelines (GHS category).

Half-Life

Hexarelin has a plasma half-life of approximately 70 minutes — significantly longer than GHRP-6 (~15–20 minutes) and shorter than ipamorelin (~2 hours). Imbimbo et al. (1994) documented that peak GH concentrations occur approximately 30 minutes after administration, with GH levels returning to baseline within 240 minutes.[1] This produces a defined, pulsatile GH response that preserves natural secretory rhythms and somatostatin-mediated feedback.

For comparison across GH-axis peptides: sermorelin has a half-life of ~10–20 minutes, CJC-1295 without DAC ~30 minutes, and CJC-1295 with DAC extends to 5–8 days. Hexarelin’s intermediate half-life balances a potent acute pulse with reasonable duration of action. The downstream effects — IGF-1 elevation, lipolysis, tissue repair signalling — operate on substantially longer timescales than the compound’s circulating presence.

Limits of Current Evidence

• Not approved anywhere: Hexarelin has never received regulatory approval for any indication in any jurisdiction. Unlike tesamorelin (FDA-approved) or semaglutide (FDA-approved), hexarelin remains exclusively a research compound.
• Desensitisation limits chronic utility: The progressive decline in GH response during sustained use is a fundamental limitation that distinguishes hexarelin from compounds like ipamorelin that maintain efficacy.[7]
• Cardioprotective data is preclinical: The CD36-mediated cardiac protection — while consistent across multiple animal models — has not been validated in human cardiac outcome studies.[3][5][6]
• Cortisol and prolactin elevation: Non-selective HPA axis stimulation positions hexarelin below ipamorelin and GHRP-2 on the selectivity spectrum.[4]
• Limited large-scale human RCTs: Most published hexarelin studies are characterisation or mechanism studies. Therapeutic-scale randomised controlled trials are absent.
• Long-term safety data is sparse: The longest published human study spans 16 weeks. Multi-year safety profiles are not established.[7]

Verdict

This hexarelin review positions the compound as a paradox within the GHRP class: the most potent acute GH secretagogue, yet the most prone to desensitisation with sustained use. For single-dose GH release potency, no other growth hormone releasing peptide matches hexarelin’s documented peak — a pharmacological fact established across multiple clinical studies.[1][2][8]

The desensitisation profile fundamentally shapes hexarelin’s practical positioning. Where ipamorelin and GHRP-2 maintain their GH response over weeks and months, hexarelin’s efficacy declines significantly within the first month of chronic exposure.[7] This limits its utility for applications requiring sustained GH elevation — including most recovery, sleep, and muscle growth contexts.

Where hexarelin holds a genuinely unique position is in cardiovascular research. The CD36-mediated cardioprotective effects — reduced infarct size, attenuated fibrosis, improved ventricular function — represent a pharmacological property that no other GHRP demonstrates to the same degree.[3][5][6] If these preclinical findings translate to human models, hexarelin may ultimately be remembered more for its cardiac applications than for its role as a GH secretagogue. For now, evaluate hexarelin as the most potent but least sustainable GHRP for GH release, with an intriguing and potentially transformative cardiovascular research frontier.

FAQ

What is hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue that activates the GHS-R1a receptor, producing the most potent acute GH release of any compound in the GHRP family. It also acts on CD36 scavenger receptors in cardiac tissue, producing cardioprotective effects independent of GH secretion. Hexarelin is not approved by any regulatory agency and remains a research compound.[1][3]

How does hexarelin differ from other GHRPs?

Hexarelin produces the strongest acute GH pulse of any GHRP but also shows the most pronounced desensitisation with repeated use. It uniquely demonstrates CD36-mediated cardioprotective effects that other GHRPs like ipamorelin and GHRP-6 do not share to the same degree. It also stimulates cortisol and prolactin, placing it lower on the selectivity spectrum than ipamorelin.[2][4][7]

Does hexarelin cause desensitisation?

Yes — hexarelin shows significant desensitisation during chronic use. Rahim et al. (1998) documented approximately 45% reduction in GH response by week 16 of continuous therapy. The desensitisation is partial and reversible, with GH response returning to baseline within 4 weeks of cessation.[7]

What are hexarelin’s cardioprotective effects?

Hexarelin cardioprotection operates through CD36 scavenger receptors in cardiac tissue, independently of GH release. Preclinical research has demonstrated reduced ischaemia-reperfusion damage, attenuated cardiac fibrosis, decreased left ventricular hypertrophy, and improved diastolic function in animal models.[3][5][6]

Does hexarelin affect cortisol?

Yes. Korbonits et al. (1999) confirmed that hexarelin significantly stimulates ACTH and cortisol release via arginine vasopressin-mediated HPA axis activation. This effect is transient but measurable, and distinguishes hexarelin from more selective compounds like ipamorelin that do not affect cortisol.[4]

Is hexarelin FDA approved?

No. Hexarelin has never received FDA approval or regulatory approval in any jurisdiction. It remains exclusively a research compound. It is also classified as a WADA prohibited substance under the growth hormone secretagogue category. For FDA-approved GH-axis compounds, see tesamorelin.

How does hexarelin compare to ipamorelin for research?

Hexarelin produces a substantially stronger acute GH pulse but desensitises with chronic use, while ipamorelin maintains its GH response over time. Ipamorelin is more selective, avoiding cortisol and prolactin elevation. Hexarelin’s unique advantage is its CD36-mediated cardioprotective profile, which ipamorelin does not demonstrate.[1][3][7]

References

1. Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. PMID: 7957536
2. Ghigo E, et al. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PMID: 9186261
3. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014;11(3):253-258. PMID: 25278975
4. Korbonits M, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab. 1999;84(7):2489-2495. PMID: 10404825
5. Torsello A, et al. Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology. 2003;144(5):1787-1792. PMID: 12697684
6. Xu X, et al. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012;303(6):H703-H711. PMID: 22842067
7. Rahim A, O’Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644-1649. PMID: 9589671
8. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207

Medical Disclaimer: This page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Hexarelin is not approved by the FDA or any regulatory agency for any indication. Always consult a qualified healthcare professional before making any decisions related to your health. The information presented reflects published research and does not imply endorsement of any compound for human use outside of supervised clinical settings.